摘要目的 系统评价克唑替尼治疗ALK阳性非小细胞肺癌(NSCLC)的疗效.方法 计算机检索PubMed、The Cochrane Library、EMbase、CBM、CNKI、VIP和WanFang Data数据库,查找克唑替尼对比化疗治疗ALK阳性NSCLC疗效的随机对照试验(RCT),检索时限均为从建库至2016年4月.由2名研究员按照纳入与排除标准筛选文献、提取资料和评价纳入研究的方法学质量后,采用RevMan 5.3软件进行Meta分析.结果 共纳入6个RCT,共838例患者.Meta分析结果显示:与化疗组相比,克唑替尼可显著提高ALK阳性NSCLC患者的有效率(RR =2.46,95％ CI:1.60～3.79,P＜0.0001),显著延长患者的无进展生存期(HR =0.47,95％ CI:0.39～0.57,P＜0.00001),并不显著延长患者的总生存期(HR =0.92,95％ CI:0.69～1.24,P=0.59).结论 克唑替尼治疗ALK阳性NSCLC患者的临床疗效优于常规化疗,可延长无进展生存期.

abstractsObjective To systematically review the efficacy of crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Methods Databases including PubMed,The Cochrane Library,EMbase,CBM,CNKI,VIP and WanFang Data were searched for the randomized controlled trials (RCTs) about crizotinib versus chemotherapy in the treatment of ALK positive NSCLC from the establishment to April 2016.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,and assessed methodological quality of the included studies.Meta-analysis was then performed using RevMan 5.3 software.Results A total of six RCTs involving 838 patients were finally included.Meta-analysis showed that:compared with the chemotherapy group,crizotinib significantly improved the response rate of the patients with ALK positive NSCLC (RR =2.46,95％ CI:1.60-3.79,P ＜0.000 1),significantly prolonged the progression free survival (HR =0.47,95％ CI:0.39-0.57,P ＜0.000 01),but did not significantly prolong the overall survival (HR =0.92,95％ CI:0.69-1.24,P =0.59).Conclusions Crizotinib is superior to standard chemotherapy in patients with ALK positive NSCLC,can prolong the progression free survival of patients.